Alx Oncology Holdings (ALXO) - Net Assets
Based on the latest financial reports, Alx Oncology Holdings (ALXO) has net assets worth $44.80 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($82.72 Million) and total liabilities ($37.92 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ALXO cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $44.80 Million |
| % of Total Assets | 54.16% |
| Annual Growth Rate | 52.14% |
| 5-Year Change | -73.57% |
| 10-Year Change | N/A |
| Growth Volatility | 31.09 |
Alx Oncology Holdings - Net Assets Trend (2018–2024)
This chart illustrates how Alx Oncology Holdings 's net assets have evolved over time, based on quarterly financial data. Also explore how large is Alx Oncology Holdings 's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Alx Oncology Holdings (2018–2024)
The table below shows the annual net assets of Alx Oncology Holdings from 2018 to 2024. For live valuation and market cap data, see ALXO market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $113.62 Million | -40.11% |
| 2023-12-31 | $189.71 Million | -27.99% |
| 2022-12-31 | $263.46 Million | -27.43% |
| 2021-12-31 | $363.05 Million | -15.54% |
| 2020-12-31 | $429.85 Million | +155840.94% |
| 2019-12-31 | $-276.00K | -103.01% |
| 2018-12-31 | $9.15 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Alx Oncology Holdings 's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 56758300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $53.00K | 0.05% |
| Other Comprehensive Income | $275.00K | 0.24% |
| Other Components | $734.41 Million | 646.39% |
| Total Equity | $113.62 Million | 100.00% |
Alx Oncology Holdings Competitors by Market Cap
The table below lists competitors of Alx Oncology Holdings ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
technotrans SE
F:TTR1
|
$221.74 Million |
|
Kolmar BNH Co. Ltd
KQ:200130
|
$221.86 Million |
|
Benz Mining Corp
F:1VU
|
$221.87 Million |
|
Audix Corp
TW:2459
|
$221.90 Million |
|
Pact Group Holdings Ltd
AU:PGH
|
$221.68 Million |
|
MFS Municipal Income Trust
NYSE:MFM
|
$221.59 Million |
|
Shanghai Supezet Engineering Technology Corp Ltd
SHG:688121
|
$221.52 Million |
|
Laboratorio Reig Jofre S.A
MC:RJF
|
$221.39 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Alx Oncology Holdings 's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 189,712,000 to 113,618,000, a change of -76,094,000 (-40.1%).
- Net loss of 134,850,000 reduced equity.
- Share repurchases of 351,000 reduced equity.
- Other comprehensive income increased equity by 19,000.
- Other factors increased equity by 59,088,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-134.85 Million | -118.69% |
| Share Repurchases | $351.00K | -0.31% |
| Other Comprehensive Income | $19.00K | +0.02% |
| Other Changes | $59.09 Million | +52.01% |
| Total Change | $- | -40.11% |
Book Value vs Market Value Analysis
This analysis compares Alx Oncology Holdings 's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.78x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 4.05x to 0.78x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $0.42 | $1.69 | x |
| 2019-12-31 | $-0.01 | $1.69 | x |
| 2020-12-31 | $10.79 | $1.69 | x |
| 2021-12-31 | $9.01 | $1.69 | x |
| 2022-12-31 | $6.47 | $1.69 | x |
| 2023-12-31 | $4.41 | $1.69 | x |
| 2024-12-31 | $2.18 | $1.69 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Alx Oncology Holdings utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -118.69%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.30x
- Recent ROE (-118.69%) is below the historical average (-61.99%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -149.98% | -664.30% | 0.19x | 1.22x | $-14.65 Million |
| 2019 | 0.00% | -401.23% | 0.45x | 0.00x | $-19.22 Million |
| 2020 | -10.64% | -3869.71% | 0.00x | 1.01x | $-88.72 Million |
| 2021 | -22.99% | 0.00% | 0.00x | 1.05x | $-119.77 Million |
| 2022 | -46.87% | 0.00% | 0.00x | 1.16x | $-149.83 Million |
| 2023 | -84.76% | 0.00% | 0.00x | 1.28x | $-179.78 Million |
| 2024 | -118.69% | 0.00% | 0.00x | 1.30x | $-146.21 Million |
Industry Comparison
This section compares Alx Oncology Holdings 's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Alx Oncology Holdings (ALXO) | $44.80 Million | -149.98% | 0.85x | $221.72 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Alx Oncology Holdings
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, und… Read more